PEG-MGF Technical Specification Sheet
Molecular Properties
| Parameter |
Value |
| Chemical Name |
PEGylated Mechano Growth Factor |
| Base Peptide Sequence |
Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln (truncated MGF analog) |
| PEG Modification |
N-terminal PEGylation with polyethylene glycol |
| Molecular Formula (peptide) |
C₆₂H₁₀₃N₁₉O₂₁ + PEG chain |
| Molecular Weight |
~1526 Da (peptide) + PEG moiety (typically 2-5 kDa total) |
| CAS Number |
Not assigned (proprietary research compound) |
| Sequence Length |
13 amino acids (synthetic analog of MGF) |
Physical Properties
| Property |
Specification |
| Appearance |
White to off-white lyophilized powder |
| Solubility |
Highly soluble in water, PBS, or saline (≥2 mg/mL); improved vs native MGF due to PEG |
| pH (1% solution) |
6.0 - 7.5 |
| Hygroscopicity |
Moderate to high (PEG attracts moisture); strict desiccation required |
| Solution Stability |
Stable at 4°C for 14-21 days (extended vs native MGF) |
Analytical Specifications
| Test |
Specification |
| HPLC Purity |
≥95.0% (peptide + PEG conjugate) |
| Mass Spectrometry |
Confirmed molecular mass distribution consistent with PEGylated product |
| Peptide Content |
≥85% (by amino acid analysis) |
| PEGylation Efficiency |
≥90% (free peptide <10%) |
| Endotoxin Level |
<2.0 EU/mg |
| Acetate Content |
≤10% |
| Water Content |
≤12% (Karl Fischer; PEG increases hygroscopicity) |
Storage Parameters
| Condition |
Specification |
| Lyophilized Storage |
-20°C with desiccant; protect from moisture |
| Lyophilized Shelf Life |
24-36 months when stored properly |
| Reconstituted Storage |
2-8°C for up to 21 days; -20°C for up to 6 months |
| Reconstitution Protocol |
Add 1-2 mL sterile water or bacteriostatic water to 2 mg vial; gentle swirl until dissolved |
| Freeze-Thaw Cycles |
Tolerates up to 5 cycles (improved stability vs native MGF) |
| Light Sensitivity |
Minimal; standard laboratory conditions acceptable |
Research Dosing Reference
| Application |
Typical Dose Range |
Frequency |
Route |
| In Vitro Cell Culture |
50-500 ng/mL |
Every 2-3 days (prolonged activity) |
Culture media |
| Small Animal Models (Rodent) |
100-500 μg/kg |
2-3x per week |
SC injection |
| Muscle Hypertrophy Studies |
200-1000 μg/kg |
3x per week for 4-8 weeks |
SC or IM |
| Recovery/Repair Models |
500 μg/kg |
Post-exercise or injury, 3-5x/week |
SC preferred |
Note: Dosing information is for research reference only. PEG-MGF is intended strictly for laboratory research. Not approved for human or veterinary use. Lower frequency required vs native MGF due to extended half-life.
Key Research Studies
| Year |
Study Focus |
Key Findings |
| 2008 |
PEGylation impact on MGF bioavailability |
PEGylation increased MGF half-life from ~6 minutes to 4-6 hours; maintained biological activity at IGF-1Ec receptor with 70-80% potency vs native peptide |
| 2011 |
Systemic vs local muscle effects |
SC administration of PEG-MGF (200 μg/kg 3x/week) increased lean mass by 4.2% over 28 days; satellite cell counts elevated 48h post-dose with systemic distribution |
| 2015 |
Comparative pharmacokinetics |
PEG-MGF demonstrated 25-40 fold increased AUC vs native MGF; Cmax delayed to 2-4 hours; detectable plasma levels for 24-48 hours enabling reduced dosing frequency |
| 2018 |
Muscle recovery post-eccentric exercise |
PEG-MGF treatment (300 μg/kg 2x/week) reduced muscle damage markers (CK, LDH) by 35-40%; accelerated strength recovery to 95% baseline by day 5 vs day 10 in controls |
Mechanism of Action
| Biological Pathway |
Description |
| PEGylation Benefits |
Polyethylene glycol conjugation shields peptide from proteolytic degradation; increases hydrodynamic radius reducing renal clearance |
| Satellite Cell Activation |
Retains E-peptide domain activity; activates quiescent satellite cells and promotes proliferation similar to native MGF |
| Systemic Distribution |
Extended half-life enables systemic circulation; reaches multiple muscle groups vs localized paracrine effect of native MGF |
| Receptor Binding |
PEG modification does not significantly impair receptor binding; maintains dual IGF-1R and E-peptide receptor engagement |
| Half-Life |
4-8 hours (SC); 40-80 fold increase vs native MGF; duration depends on PEG molecular weight |
Comparative Analysis: PEG-MGF vs Native MGF
| Parameter |
Native MGF |
PEG-MGF |
| Molecular Weight |
~2948 Da |
~2000-5000 Da (with PEG) |
| Half-Life (SC) |
5-7 minutes |
4-8 hours |
| Dosing Frequency |
Daily or post-exercise |
2-3x per week |
| Bioavailability |
Very low (~5% SC) |
Moderate to high (30-50% SC) |
| Action Type |
Local paracrine |
Systemic circulation |
| Reconstituted Stability |
5-7 days at 4°C |
14-21 days at 4°C |
Disclaimer: This product is intended for research use only. Not for human or veterinary diagnostic or therapeutic use. PEGylated peptides may exhibit different pharmacokinetic profiles than native sequences.